शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSEVASUNDHARA RASAYANS LTD· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 14 Aug, 2026 · 16:03 IST

Q1 FY27 results: revenue dips 8%, PAT grows 13%

Revenue declinedEBITDA margin expansionResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-7.5%Reaction day
₹187.00
prior close
₹172.95
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-7.7% vs market
Pharmaceuticals peers, median of 167sector-0.3%-7.2% vs sector

On the reaction day the stock moved 7.7 pts less than Nifty Microcap 250 and 7.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.0
10m
-0.0
15m
-0.0
30m
-0.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-7.5+0.1-7.7-0.3-7.2
Next day
-12.1+0.5-12.6-0.0-12.1
2d
-15.5-0.1-15.4-0.7-14.8
3d
-15.1+0.4-15.5-0.4-14.7
4d
-17.6+0.7-18.3-0.7-17.0
5d
-18.2+0.9-19.1-0.5-17.6
1w
-19.7+1.1-20.8-0.7-19.0
15d
-18.2+1.6-19.8+1.4-19.6
1m
-15.6-0.7-14.8+0.6-16.2
2m
-27.8-3.2-24.6-4.1-23.7
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q1 FY27 (June 30, 2026) unaudited results. Net sales fell to Rs 693.22 lakhs from Rs 756.15 lakhs YoY, about 8.3 percent lower. Total income dropped from Rs 824.50 to Rs 730.10 lakhs. Despite the dip, net profit after tax rose to Rs 64.80 lakhs from Rs 57.28 lakhs, up around 13 percent. EPS improved to Rs 2.04 from Rs 1.80. The company operates in agri products. Auditors issued a clean, unmodified review report.

Likely market impact

Revenue dipped 8% but PAT grew 13%, showing margin improvement. Clean audit review is reassuring.